This study is testing a new medicine called zorevunersen for children and teenagers with Dravet Syndrome, a severe form of epilepsy. Zorevunersen is designed to help the body make more of a specific protein (Nav1.1) that is often low in people with Dravet Syndrome. The study will look at how well zorevunersen reduces seizures and if it is safe. You might be able to join if you are between 2 and 17 years old and have a confirmed diagnosis of Dravet Syndrome. The main goal is to see if zorevunersen can reduce the number of major motor seizures you have by Week 28.

Study design

This is a global, randomized, double-blind study with 170 participants. This means participants are randomly assigned to receive either zorevunersen or a sham procedure, and neither you nor your doctor will know which you are receiving at first.

What's involved

Participants will receive zorevunersen or a sham procedure by injection into the spinal fluid (intrathecal administration) on several specific days over two treatment periods. The study will assess seizure changes at Week 28 and again at the end of Treatment Period 2.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured at Week 28, and assessments continue through the end of Treatment Period 2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.